Key facts
- This page summarizes RTW INVESTMENTS, LP's Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 22 Apr 2026, 16:15.
RTW INVESTMENTS, LP - 20 Apr 2026 Form 4 Insider Report for Kailera Therapeutics, Inc. (KLRA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- KLRA
- Reported as of
- 20 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Apr 2026, 16:15:07 UTC
- Prior SEC filing
- 16 Apr 2026
- Next SEC filing
- 29 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Roderick Wong, for RTW Investments, LP, By: Roderick Wong, M.D., Managing Partner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RTW INVESTMENTS, LP filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 22 Apr 2026.
Change
- Previous filing in this sequence was filed on 16 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (2)
CIK 0001493215
Primary reporting owner
RTW INVESTMENTS, LP
- Relationship
- 10%+ Owner
- Address
- 40 10TH AVENUE, FLOOR 7, NEW YORK
- Signature
- /s/ Roderick Wong, for RTW Investments, LP, By: Roderick Wong, M.D., Managing Partner
- Signature date
- 22 Apr 2026
CIK 0001493280
WONG RODERICK
- Relationship
- 10%+ Owner
- Address
- C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, FLOOR 7, NEW YORK
- Signature
- /s/ Roderick Wong, By: Roderick Wong, M.D.
- Signature date
- 22 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KLRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +10,276,820
- Change %
- Price
- Shares after
- 10,276,820
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Footnotes
- F1, F2
KLRA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +10,276,820
- Change %
- Price
- Shares after
- 10,276,820
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Footnotes
- F1, F2
KLRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +500,000
- Change %
- +4.9%
- Price
- $16.00*
- Shares after
- 10,776,820
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Footnotes
- F2
KLRA
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +500,000
- Change %
- +4.9%
- Price
- $16.00*
- Shares after
- 10,776,820
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KLRA
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -8,250,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,250,000
- Exercise price
- Footnotes
- F1, F2
KLRA
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -8,250,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 8,250,000
- Exercise price
- Footnotes
- F1, F2
KLRA
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,026,820
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 2,026,820
- Exercise price
- Footnotes
- F1, F2
KLRA
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -2,026,820
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 20 Apr 2026
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 2,026,820
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
RTW INVESTMENTS, LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date.
Footnote F2
Held by certain affiliated funds managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.